Somewhat Favorable Press Coverage Somewhat Unlikely to Impact FibroGen (FGEN) Share Price
Headlines about FibroGen (NASDAQ:FGEN) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. FibroGen earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.846748127246 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern’s analysis:
- Comparing FibroGen (FGEN) and Celyad (CYAD) (americanbankingnews.com)
- FibroGen (FGEN) Downgraded by BidaskClub to Sell (americanbankingnews.com)
- Trend Analysis Report: Itron, Inc., (NASDAQ: ITRI), FibroGen, Inc., (NASDAQ: FGEN), Adamas Pharmaceuticals, Inc … – Stocks In The News (press release) (tradingnewsnow.com)
- Analysts Predict 22% Upside For PBE – Nasdaq (nasdaq.com)
- Insider Buying: FibroGen, Inc (FGEN) Director Acquires 3,500 Shares of Stock (americanbankingnews.com)
Several equities analysts recently commented on FGEN shares. Jefferies Group reissued a “buy” rating and issued a $75.00 target price on shares of FibroGen in a report on Tuesday, September 12th. Stifel Nicolaus reaffirmed a “buy” rating and set a $80.00 price objective on shares of FibroGen in a report on Thursday, September 14th. Mizuho began coverage on FibroGen in a report on Wednesday, October 4th. They set a “neutral” rating and a $61.00 price objective on the stock. ValuEngine lowered FibroGen from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, BidaskClub lowered FibroGen from a “hold” rating to a “sell” rating in a report on Thursday. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $65.67.
In other news, CEO Thomas B. Neff sold 38,636 shares of the stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $51.67, for a total transaction of $1,996,322.12. Following the completion of the sale, the chief executive officer now owns 3,297,655 shares in the company, valued at $170,389,833.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Gerald Lema bought 3,500 shares of the firm’s stock in a transaction dated Monday, December 4th. The shares were acquired at an average price of $46.70 per share, with a total value of $163,450.00. Following the purchase, the director now directly owns 3,500 shares of the company’s stock, valued at approximately $163,450. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 397,131 shares of company stock worth $21,109,380. Corporate insiders own 13.60% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-fibrogen-fgen-share-price/1758345.html.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.